Bukhari Nedal, Al-Shamsi Humaid O, Azam Faisal
Department of Medical Oncology, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia.
Associate Professor, University of Sharjah, Sharjah, UAE.
ScientificWorldJournal. 2018 Jun 6;2018:5682078. doi: 10.1155/2018/5682078. eCollection 2018.
Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years. Clinical trials are currently ongoing to determine how best to use and sequence these treatments. In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy. This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.
铂类联合化疗一直是转移性尿路上皮癌（mUC）一线治疗的标准方案。在过去几年中，铂类方案治疗进展后的转移性疾病治疗有了显著进展。目前正在进行临床试验，以确定如何最佳地使用这些治疗方法并安排其顺序。在这篇小型综述中，我们将回顾顺铂适用和不适用患者的当前一线治疗选择，以及一线和二线治疗（包括化疗和免疫治疗）的进展。本综述报告了临床试验的关键发现，特别强调了PD-1和PD-L1抑制剂在膀胱/尿路上皮癌治疗中的重要性。
